S P E C T R E

#REE 1/7 | What is the market missing? A massive discount. The REE ticker hides three verified, high-value assets (Fluorspar, Gallium, Copper) being rapidly advanced. The stock is about to catch up to the intrinsic value. Read why below 🧵 altonare.com

#REE Altona Rare Earths up 177% YTD.

@Solvonis Now we know why the CEO Anthony Tennyson disappeared from X. He was busy securing two distinct US patents for the PTSD discovery program.

#SVNS Testing the resistance at 0.28p. Momentum is building after SVN-114 selection and rapid-fire patent grants. Clearing this resistance should open the window for a re-rating toward 52-week highs, but the legacy sellers may have other ideas.

#SVNS @Solvonis is still trading underwater vs October placing 0.33p, despite significant newsflow since then. Selection of SVN-114 and dual patent grants are scientific wins. The market requires execution.

@MikeMikemufc a roughly 4x increase? That would be nice. The warrant overhang is the primary friction point preventing a clean re-rating at the moment.

@Spectre_Trader Under 13m mc ,got to be 50m before long

#REE Altona Rare Earths is effectively coiled at the 2.95p level. With all final assays now in hand and the JORC Mineral Resource Estimate (MRE) confirmed for an April release, is the market beginning to anticipate a major re-rate?

#SVNS Patents are paper milestones. They secure the future, they don't pay the bills today. Is the market still absorbing the 0.33p October placing supply? The share price is lagging. This churn is never ending.

$SVNS Solvonis secures second US patent for PTSD drug programme within a week tinyurl.com/2392plad @Solvonis #SVNS

#REE The wait for @AltonaRareEarth updated MRE is nearly over. Following the final assay results in late March, the maiden JORC Resource for fluorspar and gallium is scheduled for release in April 2026, assuming all circumstances remain the same.

#SVNS Q1 technical targets hit: SVN-114 selected as lead PTSD candidate and crucial US composition-of-matter patent granted. Focus now shifts to Q2 operational catalysts: pending non-dilutive grant awards and IND-enabling studies. Valuation gap remains vs CNS peers.

#SVNS There is a global shortage of de-risked CNS assets. @Solvonis recently selected SVN-114 as its lead candidate for PTSD. A market Lilly’s multi-billion dollar $CENT deal proves is a top strategic priority for major players.

#SVNS is recovering very slowly. Only -18.75 YTD

@Rrockypolos A penny for your thoughts? #SVNS

@Rrockypolos @HandGrenad89912 #SVNS We are seeing sustained buy side pressure. Some weighty prints.

@HandGrenad89912 @Spectre_Trader It's looking good today I have to say. Those are some very big trades going through. Best of luck. Could be your time

And so goes Q1 and missed deadlines. What also happened to the 'in discussions with 3 pharmas' at the end of Q4 2025? #svns Ant Tennyson can only string this along a little while longer before investors start to question his position. Today's news good but still too much promised

@HandGrenad89912 @Rrockypolos @RoastPR Is Anthony Tennyson, CEO of Solvonis Therapeutics, scheduled to talk on your podcast about US$1bn+ deal comparisons, and is this optimism realistic?

@Rrockypolos @Spectre_Trader Supposedly, AT is due to have a chat on the Sunday Roast very soon.

@Rrockypolos @HandGrenad89912 #SVNS The current share price is still roughly 20% below the 0.33p placing price.

@HandGrenad89912 @Spectre_Trader 🤣wish you the very best fellas. Maybe Tuesday is the day I'll be really kicking myself

@Rrockypolos @HandGrenad89912 Don't speak too soon.

@HandGrenad89912 @Spectre_Trader Looking lively today. So all good it seems

@HandGrenad89912 @Rrockypolos Amateur hour.

@Rrockypolos @Spectre_Trader It is today. However, like the football team I support, it's better for everyone if I don't watch!

@Spectre_Trader My favourite bet 😉.

#SVNS Harsh reality: No data, no deal.

#SVNS With the £1.25m raise from October 2025 likely depleting, the focus on grants suggests a desire to avoid another dilutive placing. If a deal were imminent, the March lead selection was the near-perfect trigger.